The National Legal and Policy Center (NLPC) will present a shareholder proposal at Visa's annual meeting challenging the company's health insurance policies regarding gender-transitioning treatments. The proposal aims to investigate potential risks and compensation gaps for employees affected by gender-switching medical procedures. Claire Abernathy, a 20-year-old detransitioner, will speak at the meeting about her personal experience with gender-related medical interventions. Abernathy described how therapists and medical professionals rapidly guided her into body-altering procedures beginning when she was just 12 years old. Within eight months of initial therapy referral, she underwent a double mastectomy and was prescribed testosterone.
The NLPC's shareholder proposal highlights several medical procedures currently covered by Visa's CIGNA health insurance, including mastectomies, penectomies, vaginectomies, orchiectomies, and salpingooophorectomies. Paul Chesser, director of NLPC's Corporate Integrity Project, criticized these coverage policies as "radical medical experiments". The proposal draws attention to potential legal and ethical considerations surrounding gender-transition healthcare. The Equal Employment Opportunity Commission considers failure to provide equivalent benefits based on gender identity as discriminatory. The Securities and Exchange Commission has previously acknowledged that de-transitioning individuals could be classified under such considerations.
Abernathy emphasized the importance of comprehensive healthcare, stating that "true equity in healthcare means acknowledging the full range of outcomes in gender transitioning treatments, and ensuring that all individuals have access to the care that they need." NLPC has previously sponsored similar proposals at other major corporations, including Johnson & Johnson and PepsiCo, indicating a broader corporate governance initiative addressing healthcare policy concerns. The organization maintains a website at https://nlpc.org where it publishes information about its corporate integrity initiatives. The proposal represents a growing scrutiny of corporate healthcare policies that extends beyond traditional benefits discussions to include complex medical and ethical dimensions.
